Pancreatic polypeptide (PP), a recently discovered pancreatic hormone, is potentially a marker for endocrine tumors. Consequently, we devised a radioimmunoassay for it, using antisera (raised in rabbits) to bovine PP, 1251-labeledbovine PP (purified by anion-exchange chromatography),and human PP standards. Concentrations circulating in fasting, normal subjects were measured. Statistical analysis of the results revealed a skewed distribution. An age-related increase was also observed. Evaluating PP concentrations in sera from 23 patients with endocrine tumors, we found increased values in a few cases of Zollinger-Ellison syndrome, medullary carcinoma of the thyroid, carcinoid syndrome, and one tumor producing vasoactive intestinal polypeptide (VIPoma). In contrast, values from five insulinomas and one glucagonoma were within the normal reference interval. Thus, an increased value for PP in a fasting individ- Pancreatic polypeptide (P),1 a 36-residue peptide, was discovered as a contaminant during the chemical purification of insulin (1), rather than by virtue of any distinct biological action. It has been localized predominantly to distinct endocrine cells of the pancreatic islets (2). Chemical characterization of PP derived from certain birds and mammals has revealed differences in primary structure, which may reflect differences in observed biological activity. hn birds, the peptide has a metabolic role, primarily in hepatic glycogenolysis but possibly also in lipogenesis (3). In humans, PP inhibits gall-bladder contraction and, to a lesser extent, pancreatic exocrine secretion (4). Hyperplasia of PPcontaining cells, in association with increases in its circulating concentrations, has been observed in patients with "mixed-type" pancreatic endocrine tumors (5) and in a proportion of patients with "VlPomas" (tumors that produce vasoactive intestinal polypeptide) or the "watery diarrhea hypokalemic achlorhydric" syndrome (6).
Antibody production. We used two methods of conjugating antigen to the carrier protein:
I. Carbodiimide conjugation (7). This conjugate was propared from 600 g of bovine PP, 250 g of rabbit albumin, and 0.5 mg of freshly weighed carbodiimide (hygroscopic substance).
II. Glutaraldehyde conjugation (8).
This conjugate was prepared by adding 600 g of bovine PP and 250 g of rabbit albumin to 2 mL of 40 milL glutaraldehyde solution. The efficiency of the conjugation methods was determined by estimating the amount of unconjugated PP present, by precipitating large-Mr (relative molecular mass) conjugated PP with absolute ethanol. The maximum percentage of unconjugated PP was 0.4%. We immunized three rabbits and one sheep with bovine PP conjugated by use of method I, and designated them PP204, PP205, PP206, and S98, respectively. Three rabbits-PP207, PP208, and PP209-were immunized by use of coupling method II. The primary immunization in each case consisted of approximately 100 pg of bovine PP in 1 mL of Freund's complete adjuvant, injected subcutaneously at multiple sites. Secondary immunization, administered six weeks later, consisted of approximately 50 pg of antigen in 1 mL of Freund's adjuvant (1/10, by vol, mixture of complete/incomplete), injected at a single site. We investigated the cross reactivity of the bovine PP antisera by testing them with human PP, bovine PP, the Cterminal hexapeptide of PP, insulin, gastrin, secretin, vasoactive intestinal polypeptide (VIP), gastric inhibitory polypeptide, and somatostatin.
Two recently isolated peptides, neuropeptide Y and peptide YY (9,10), which have considerable sequence homology with PP, were also tested for cross reactivity with the antisera.
Preparation of iodinatedPP.
We added 1 mCi of 1251 to 10 pg of bovine PP in 100 L of phosphate buffer (0.2 molJL, pH 7.2) and stirred this at room temperature before adding 10 .tL of a 2 g/L solution of Chloramine T. After 15 s, we added 100 L of sodium metabisulfite (0.5 g/L solution) to terminate the reaction. After stirring the mixture for a further 40 s, we added 50 .tL of a 10 g/L solution of potassium iodide. The resulting 1I-labeled bovine PP was promptly purified at 4 #{176}C by anion-exchange chromatography, as follows. To a 30 x 0.9 cm column of QAE Sephadex A-25 equilibrated with Tris HC1 buffer (80 mmoli'L, pH 8.0) containing 2 g of human albumin per liter, we applied the labeled PP and eluted it with the same buffer solution at 7 mL/h. Fractions showing peaks corresponding to h-labeled bovine PP were pooled and stored in an equal volume of acidified ethanol (ethanol/concentrated HC1, 99/1 by vol) at -20 #{176}C. We determined the elution profile of nonlabeled peptide by eluting standard bovine PP under the same conditions as for 'WI-labeled bovine PP.
Radioimmunoassay constituents.
Human PP, the standard in our radioimmunoassay, was stored in aliquots at -20 #{176}C in phosphate buffer (40 mmol/L, pH 7.4) containing 2 g of human albumin per liter. Before radioimmunoassay, the human PP was thawed and diluted to concentrations ranging from 19.5 to 1250 ng/L. The diluent was an ethanolic extract of horse serum, reconstituted in phosphate buffer, 40 mmol/L, pH 7,4. The horse serum had previously been stripped of endogenous peptides by treatment with activated charcoal (11).
Antiserum obtained from rabbit PP205 was used at a final assay dilution of 72 000-fold. The antiserum was stored at 1000-fold dilution at -20 #{176}C, then thawed and diluted prior to assay in the phosphate buffer containing horse serum (20 mLIL).
1251-labeled bovine PP was diluted in the phosphate buffer containing horse serum to give 100 counts/s per 100-pL aliquot.
Analytical
samples.
Blood samples for PP analysis were withdrawn, collected in heparinized tubes, and cooled to 4 #{176}C. After centrifugation at 1000 x g for 20 mm, 1-mL aliquots of plasma were extracted with 1.6 mL of absolute ethanol. The supernate obtained after further centrifugation (1500 x g, 20 mm) was dried under a stream of air, stored at 4#{176}C, and reconstituted in phosphate buffer (40 mmollL, pH 7.4) before assay. When necessary, analytical samples were diluted with standard diluent.
PP recovered from plasma. Stock standard used in the radioimmunoassay was diluted with charcoal-stripped plasma, then extracted with absolute ethanol in the same proportion as for the samples. Dried extracts were reconstituted in phosphate buffer (40 mmol!L, pH 7.4) and included in each assay as control recovery samples.
Procedures

All radioimmunoassay procedures
were performed at 4 #{176}C. Standards or analytical samples (100 FL), antiserum (100 ML), and standard diluent (100 4) were incubated for 48 h before the addition of labeled peptide (100 4). After a further 48 h, antibody-bound and free peptide were separated by using dextran-coated charcoal (12). To assess the percentage of free labeled peptide in the charcoal pellet, obtained by centrifugation at 1500 x g for 30 mm, we used a gamma counter (NE 1600; Nuclear Enterprise Ltd., Sighthill, Edinburgh, U.K.).
Clinical studies
Stability of PP in whole blood. Blood samples were drawn from six normal volunteers and cooled to 4 #{176}C. The plasma was separated and extracted for PP estimation immediately, and at various intervals thereafter, to assess the degradation of PP in whole blood. We determined the effect of Trasylol by adding it, 500 K.I.U./mL, to blood samples immediately after sampling (n 5).
Circulating
PP concentrations in fasting normal subjects.
Circulating concentrations of PP were measured in normal volunteers with no history of gastrointestinal or endocrine disorders. The age, sex, and weight of each subject were recorded.
Basal PP concentrations.
Fasting PP concentrations were estimated in 29 of the volunteers, at 15-mm intervals over a 1-h period, to assess baseline fluctuation. 
Circulating
Results
Assay Components
Antibody production.
With the immunization program described, two of three animals from each group produced high-titer antibodies to bovine PP. Antisera PP204 and PP205, produced with the carbodiimide-conjugating method, showed similar cross reactivity with human and bovine PP but did not cross react with the C-terminal hexapeptide, thereby indicating that they were not C-terminal specific. Antisera PP208 and PP209, produced with the glutaraldehyde-conjugating method, showed poor sensitivity in detecting both human and bovine PP; however, they cross reacted with the C-terminal hexapeptide at concentrations in excess of 1 j.og/L. The sheep, after repeated boosting, produced lowtiter antisera, which were unsuitable for use. None of the antisera demonstrated any cross reactivity with other available peptides (insulin, gastrin, secretin, VIP, gastric inhibitory polypeptide, glucagon, somatostatin, neuropeptide Y, and peptide YY). tive peak provided a standard curve of greater sensitivity than the first-eluted peak and was therefore routinely used as tracer. Figure 2 demonstrates the superimposition of the dilution curve of labeled bovine PP and a standard ctirve for human PP standards.
Radioimmunoassay
of PP. The efficiency of the extraction procedure used to measure PP was investigated by adding the peptide, in predetermined amounts, to charcoal-stripped plasma. The average analytical recovery was 89.6%. The precision of the assay was calculated by determining the standard deviation of replicate determinations.
In the sensitive region of the calibration curve this was 5 ng/L, in the intermediate region, 22 ng/L, and in the insensitive region, .39 ng/L. The intra-assay coefficient of variation was 8.6%. The interassay coefficient of variation was 12.8%. The assay could distinguish 15 ng/L from zero with 95% confidence.
Clinical Studies
Degradation of PP in whole blood. We estimated PP concentrations in extracted blood samples. When processing of the samples was delayed for 3 h, the mean recovery of PP was 90.2 (SEM 5.6)% of that of samples that were processed immediately. After 7 h the recovery of PP decreased to 90 (7.7)%. When Trasylol was added to samples, the recovery after 3 h of'delay was 94.8 (5.7)% and after 7 h 98.6 (0.8)%.
Circulating
PP concentrations
in fasting normal subjects. We estimated circulating concentrations of PP in 296 normal fasting volunteers, ages 13-84 years. Figure 3 demonstrates that the distribution curve for circulating PP concentrations in these subjects is skewed when age is not taken into account. When age is considered (Figure 4) , the PP concentrations correlate positively with it (r = 0.41, p < 0.001). Approximately 90% of subjects had a circulating PP concentration of < 150 ng/L, and the three subjects with PP concentrations in excess of 400 ng/L were older than 80 years. We saw no significant sex-related differences in PP concentrations.
Basal PP concentrations. Figure 5 shows a decrease in circulating concentrations, followed by an increase, during continual sampling in the fasted state. Statistical analysis of results (paired t-test) showed significant differences, be- 
Circulating
PP concentrations in fasting patients with
endocrine tumors. Figure 6 shows the circulating PP concentrations in fasting patients with endocrine tumors. In the radioimniunoassay for human PP we describe, we used an antiserum (PP205) raised to bovine PP conjugated to rabbit albumin by means of carbodiimide. This agent is Discussion suitable for raising antisera to bovine PP, which cross react with the human peptide; however, these antisera are not Cterminal specific. Antisera produced by the glutaraldehydeconjugating method have inferior binding to both the bovine and human peptides but may be directed more specifically towards the C-terminal region. lodination of bovine PP by a modification of the Chloramine T method produced two distinct peaks of 'I-labeled bovine PP. The standard curves constructed with use of these labeled preparations were not identical, the material in the second peak producing a more sensitive curve than the first. PP contains four potential iodination sites at positions 7, 20, 27, and 36(13).
None of the insulinoma
The presence of two peaks of 'WI-labeled bovine PP suggests that there is more than one iodinated form of PP.
The assay has been used to determine normal circulating concentrations of PP in both sexes (ages 13-84 years), an investigation of the age and sex distribution of hormone concentrations being essential before those concentrations measured in disease states can be interpreted. We found no sex-related variations in concentrations of PP; therefore, we cannot confirm the previously reported observation of Track et al. (14) , who measured greater PP concentrations in men than in women. However, we do confirm the observed increase in PP concentrations with age (15) . 
